Simulations Plus (NASDAQ:SLP) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Simulations Plus (NASDAQ:SLP) posted its quarterly earnings data on Wednesday. The technology company reported $0.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.04, MarketWatch Earnings reports. Simulations Plus had a net margin of 21.05% and a return on equity of 6.01%. During the same quarter in the previous year, the company posted $0.12 EPS.

Shares of SLP stock traded up $3.98 on Friday, hitting $49.86. 442,905 shares of the company’s stock traded hands, compared to its average volume of 225,981. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of 107.93, a P/E/G ratio of 6.44 and a beta of 0.07. Simulations Plus has a one year low of $36.90 and a one year high of $90.92. The company’s fifty day simple moving average is $50.15 and its 200 day simple moving average is $47.55.

The firm also recently announced a quarterly dividend, which was paid on Monday, November 1st. Investors of record on Monday, October 25th were issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend was Friday, October 22nd. Simulations Plus’s dividend payout ratio is currently 52.17%.

In other Simulations Plus news, Director Walter S. Woltosz sold 12,332 shares of the firm’s stock in a transaction on Friday, November 26th. The shares were sold at an average price of $48.93, for a total value of $603,404.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Walter S. Woltosz sold 7,668 shares of the firm’s stock in a transaction on Monday, November 29th. The stock was sold at an average price of $47.56, for a total transaction of $364,690.08. The disclosure for this sale can be found here. In the last three months, insiders sold 40,000 shares of company stock worth $1,874,495. Insiders own 23.08% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in SLP. Morgan Stanley boosted its stake in shares of Simulations Plus by 43.4% during the 3rd quarter. Morgan Stanley now owns 158,444 shares of the technology company’s stock valued at $6,258,000 after purchasing an additional 47,980 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Simulations Plus by 184.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,319 shares of the technology company’s stock valued at $605,000 after purchasing an additional 9,929 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Simulations Plus during the 3rd quarter valued at about $245,000. OLD Mission Capital LLC bought a new stake in shares of Simulations Plus during the 3rd quarter valued at about $309,000. Finally, Jane Street Group LLC boosted its stake in shares of Simulations Plus by 78.0% during the 3rd quarter. Jane Street Group LLC now owns 6,543 shares of the technology company’s stock valued at $259,000 after purchasing an additional 2,867 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently weighed in on SLP shares. Sidoti started coverage on shares of Simulations Plus in a research report on Tuesday. They set a “neutral” rating on the stock. Craig Hallum raised shares of Simulations Plus from a “hold” rating to a “buy” rating and reduced their target price for the company from $65.00 to $53.00 in a report on Tuesday, October 26th. Finally, Zacks Investment Research raised shares of Simulations Plus from a “sell” rating to a “hold” rating in a report on Wednesday, December 29th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $60.67.

About Simulations Plus

Simulations Plus, Inc provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the following segments: Simulations Plus, Cognigen, DILIsym and Lixoft. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students.

Featured Story: What does an outperform rating mean?

Earnings History for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.